# [¹⁴C] Hydronidone Mass Balance Study

> **NCT07471217** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Beijing Continent Pharmaceutical Co, Ltd.** · enrollment: 8 (estimated)

## Conditions studied

- Chronic Hepatitis B-related Liver Fibrosis

## Interventions

- **DRUG:** [¹⁴C]Hydronidone

## Key facts

- **NCT ID:** NCT07471217
- **Lead sponsor:** Beijing Continent Pharmaceutical Co, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07471217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07471217, "[¹⁴C] Hydronidone Mass Balance Study". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT07471217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*